Allergan Plc (AGN)

164.26
NYSE : Health Technology
Prev Close 166.08
Day Low/High 164.21 / 166.21
52 Wk Low/High 114.27 / 197.00
Avg Volume 3.91M
Exchange NYSE
Shares Outstanding 327.82M
Market Cap 54.45B
EPS -15.30
P/E Ratio N/A
Div & Yield 2.96 (1.76%)
Allergan Tumbles After Swinging to Fourth-Quarter Loss

Allergan Tumbles After Swinging to Fourth-Quarter Loss

Botox maker reports a fourth-quarter loss of $4.3 billion, a reversal from a year-earlier profit of $3.05 billion.

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon

What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.

Allergan Reports Fourth Quarter And Full-Year 2018 Financial Results

Allergan Reports Fourth Quarter And Full-Year 2018 Financial Results

- Full-Year 2018 GAAP Net Revenues of $15.8 Billion; Q4 2018 GAAP Net Revenues of $4.1 Billion -

New BOTOX® Cosmetic (onabotulinumtoxinA) "Own Your Look" Campaign Brings Fresh Face To Trusted Brand

New BOTOX® Cosmetic (onabotulinumtoxinA) "Own Your Look" Campaign Brings Fresh Face To Trusted Brand

Campaign targets new generation of users with an updated, modern approach

Earnings Preview: Apple, AMD, Verizon, Other Giants to Report Crucial Q4

Earnings Preview: Apple, AMD, Verizon, Other Giants to Report Crucial Q4

Eight important companies report earnings between Monday and Tuesday. Don't miss them.

Allergan Could Retest Its December Low Before a Better Rally Attempt

Allergan Could Retest Its December Low Before a Better Rally Attempt

Allergan could move higher but some sort of retest of the December low seems in order in the short to intermediate term.

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

ALLERGAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

ALLERGAN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Allergan Plc. - AGN

NEW ORLEANS, Jan. 25, 2019 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 19, 2019 to file lead plaintiff applications in a securities class action lawsuit against Allergan plc.

Allergan Announces Increased Quarterly Dividend And Annual General Meeting Of Shareholders Date

Allergan Announces Increased Quarterly Dividend And Annual General Meeting Of Shareholders Date

- First Quarter 2019 Cash Dividend of $0.74 Per Ordinary Share to be Paid on March 15, 2019; Record Date of February 15, 2019 -

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab

Study Evaluated Pharmacokinetics, Efficacy and Safety of ABP 798 Compared to Rituximab in Patients With Moderate-to-Severe Rheumatoid Arthritis

Jim Cramer: What Are We to Make of Today's Market Decline?

Jim Cramer: What Are We to Make of Today's Market Decline?

Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?

Power of Positives: Cramer's 'Mad Money' Recap (Thursday 1/17/19)

Power of Positives: Cramer's 'Mad Money' Recap (Thursday 1/17/19)

Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

So far 2019 is proving to be a year where things have a habit of working out right.

Try This Allergan Two-Week Setup

Try This Allergan Two-Week Setup

The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.

Tumultuous, but Positive: Cramer's 'Mad Money' Recap (Friday 1/11/19)

Tumultuous, but Positive: Cramer's 'Mad Money' Recap (Friday 1/11/19)

This will be the craziest reporting season we've seen in ages, says Jim Cramer. He's got your game plan for next week.

Allergan Must Prove Itself With Signs of More Aggressive Buying

Allergan Must Prove Itself With Signs of More Aggressive Buying

A three-year decline in the shares of the maker of Botox will take more than a two-week bounce to reverse.

FAANG Is Back: Cramer's 'Mad Money' Recap (Tuesday 1/8/19)

FAANG Is Back: Cramer's 'Mad Money' Recap (Tuesday 1/8/19)

Plus: Jim Cramer interviews Apple CEO Tim Cook about innovation, investments and healthcare technology.

Real Money Post Industrial Average Outperformed the Market in 2018

Real Money Post Industrial Average Outperformed the Market in 2018

The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.

The Charts of Allergan Look Very Bearish With New Lows Made Yesterday

The Charts of Allergan Look Very Bearish With New Lows Made Yesterday

When I looked at the charts this morning I found a stock that could still decline further.

Fighting the Fed: Cramer's 'Mad Money' Recap (Wednesday 12/19/18)

Fighting the Fed: Cramer's 'Mad Money' Recap (Wednesday 12/19/18)

Buying stocks now means you are in the uncomfortable position of fighting the Fed as it tries to slow the economy.

Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center

Jim Cramer: My Take on These Companies Where Lawsuits Are Front and Center

These are currently situations where companies are facing serious lawsuits.

Allergan Pulls Breast Implant Off European Markets Due to Cancer Risk

Allergan Pulls Breast Implant Off European Markets Due to Cancer Risk

Allergan's textured breast implants have been linked to a rare form of cancer.

Who Are the 9 Highest-Paid CEOs and How Much Do They Make?

Who Are the 9 Highest-Paid CEOs and How Much Do They Make?

The CEOs who bring in the most money every year may not be who you expect. Who are the highest-paid CEOs?

Aegon Is Driving Financial Performance Through Simplification And Growth

Aegon Is Driving Financial Performance Through Simplification And Growth

At today's Analyst and Investor Conference hosted in New York, CEO Alex Wynaendts and Aegon's US management team will outline how targeted actions to simplify and grow the business are creating significant value for all stakeholders.

I Anticipated Some Volatility Today but I Didn't Expect a Total Collapse

Still, there were some bullish aspects to the action today much as you might think otherwise.

Upcoming Portfolio Review

We'll be out later with key thoughts from our discussion on what direction the portfolio should be taken as we quickly approach a new investment year.

Aegon UK Extends Partnership With Atos For Administration Services

Aegon UK Extends Partnership With Atos For Administration Services

Aegon today announces that its subsidiary in the United Kingdom has strengthened its existing partnership with Atos, signing a 15-year contract to service and administer its Existing Business (non-platform customers).

Aegon Will Propose To Reappoint Alex Wynaendts As CEO

Aegon Will Propose To Reappoint Alex Wynaendts As CEO

Aegon's Supervisory Board will propose to the Annual General Meeting of Shareholders in May 2019 to reappoint Alex Wynaendts (58) as Chief Executive Officer of the company, for a four-year term.

Allergan Needs to Rebase on the Charts - Don't Rush It

Allergan Needs to Rebase on the Charts - Don't Rush It

Let's check the charts and technical indicators for some guidance.

TheStreet Quant Rating: C (Hold)